Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Although anti-PD-1 therapy, alone or in combination with an anti-CTLA-4 agent, has become the first-line standard of care for ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

A study led by UCLA has discovered that JAK inhibitors could potentially prevent or reverse immune-related diabetes triggered ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

A team of researchers has identified a potential new strategy to prevent, or even reverse, immune checkpoint ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...